The $580,000 purchase order from a order from a top-tier academic medical center provides a key commercial reference, supporting Inspira's ongoing strategic process. Traders should watch for potential partnership, licensing, or monetization announcements related to the ART100 platform, which could unlock further value. With a market cap of only $2M, this order represents meaningful revenue relative to scale.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 18 $0.0830entry
- T+1 · 6mo ago +71.08%α +71.73% · $0.1420
- T+5 · 6mo ago +213.25%α +211.63% · $0.2600
- T+20 · 5mo ago +57.83%α +56.25% · $0.1310
- T+60 · due 3mo ago Pending
Price Chart
How similar events traded
Executive Summary
Inspira Technologies received a $580,000 commercial purchase order from NYU Langone Hospital for its FDA-cleared ART100 extracorporeal blood circulation systems, blood circulation systems. The order follows a multi-patient clinical evaluation at NYU Langone and is scheduled for immediate fulfillment.
Key Facts
- Inspira received a $580,000 purchase order from NYU Langone Hospital for the ART100 system.
- The order was placed through Inspira received follows a multi-patient clinical evaluation involving more than 30 patients.
- The ART100 system is FDA-cleared for cardiopulmonary bypass procedures.
- The systems are scheduled for immediate fulfillment.
- Inspira disclosed it is advancing an 'active strategic process' involving multiple counterparties regarding the ART100 platform and additional medical assets.
Financial Impact
$580,000 commercial purchase order from NYU Langone Hospital.
Risk Factors
- The order is a single, modest transaction that may not extrapolate to scale.
- The company is actively seeking to monetize ART100 and other medical assets, there is no guarantee of a favorable transaction.
- No financial details or profitability impact disclosed; historical 20-F shows pre-revenue stage.
- Warrant ticker IINNW is highly speculative, volatile and prone to large price swings irrespective of news quality.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001185185-26-001890 |
| Document: iinnex99-1.htm | 0001185185-26-001890 |
| Document: 0001185185-26-001890-index-headers.html | 0001185185-26-001890 |
| Document: 0001185185-26-001890-index.html | 0001185185-26-001890 |
| Document: 0001185185-26-001890.txt | 0001185185-26-001890 |
Track record
11 reports on IINNW
1 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +63.33% at T+5 after the Apr 13, 2026 report. 1 of 4 went positive at some point.
Filters
- May 19, 202625w ago 6-K Neutral 4/10 Entry $0.1420 to $0.1200 ▼ −15.49% −16.48% vs SPY
- May 18, 202626w ago 6-K Bullish 6/10 Viewing Entry $0.0830 to $0.1310 ▲ +57.83% +56.25% vs SPY
- Apr 16, 202630w ago 6-K Bullish 7/10 Entry $0.1100 to $0.0690 ▼ −37.27% −43.09% vs SPY
- Apr 16, 202630w ago 6-K Neutral 3/10 Entry $0.1100 to $0.0690 ▼ −37.27% −43.09% vs SPY
- Apr 15, 202630w ago 6-K Neutral 3/10 Entry $0.1100 to $0.0690 ▼ −37.27% −43.09% vs SPY
- Apr 14, 202630w ago 6-K Neutral 3/10 Entry $0.0720 to $0.0690 ▼ −4.17% −10.46% vs SPY
- Apr 13, 202631w ago 6-K Bullish 7/10 Entry $0.0600 to $0.0690 ▲ +15.00% +7.27% vs SPY
- Apr 6, 202632w ago 6-K Bullish 8/10 Entry $0.1000 to $0.0680 ▼ −32.00% −40.98% vs SPY
- Apr 6, 202632w ago 6-K Bullish 7/10 Entry $0.1000 to $0.0680 ▼ −32.00% −40.98% vs SPY
- Mar 31, 202632w ago 6-K Neutral 4/10 Entry $0.0800 to $0.0690 ▼ −13.75% −23.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers